Toward a dynamic theory of antibiotic resistance

System Dynamics Review

Volumn 16, Issue 4, 2000, Pages 287-319

  Homer, Jack ^a,b,c,i   Ritchie Dunham, James ^d,e,f   Rabbino, Hal ^d   Puente, Luz Maria ^d   Jorgensen, James ^g   Hendricks, Kate ^h  

^a Homer Consulting   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d Strategic Decision Simulation Group   (United States)

^e UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^f INSTITUTO TECNOLÓGICO AUTÓNOMO DE MÉXICO   (Mexico)

^g UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^h TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0345893695     PISSN: 08837066     EISSN: None     Source Type: Journal    
DOI: 10.1002/sdr.200     Document Type: Article

References (49)

1. Austin DJ, Kakehashi M, Anderson RM. 1997. The transmission dynamics of antibiotic-resistant bacteria: the relationship between resistance in commensal organisms and antibiotic consumption. Proceedings of the Royal Society of London Series B 264: 1629-1638.
2. Austin DJ, Kristinsson KG, Anderson RM. 1999. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proceedings of the National Academy of Science USA 90: 1152-1156.
3. Ballow CH, Schentag JJ. 1992. Trends in antibiotic utilization and bacterial resistance: report of the National Nosocomial Resistance Surveillance Group. Diagnostic Microbiology of Infectious Diseases 15: 37S-42S.
4. Baquero F, Baraibar R, Campos J et al. 1996. Antibiotic resistance in Spain: what can be done? Clinical Infectious Diseases 23: 819-823.
5. Breiman RF, Butler JC, Tenover FC et al. 1994. Emergence of drug-resistant pneumococcal infections in the United States. Journal of the American Medical Association 271(23): 1831-1835.
6. Bright C. 1999. Super-bacteria arrive. World-Watch (March/April 1999): 9-11.
7. Butler JC, Hofmann J, Cetron MS et al. 1996. The continued emergence of drug-resistance Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. Journal of Infectious Diseases 174: 986-993.
8. Centers for Disease Control and Prevention (CDC). 1996. Defining the public health impact of drug-resistant Streptococcus pneumoniae: report of a working group. Morbidity and Mortality Weekly Report 45(RR-1): 1-20.
9. Centers for Disease Control and Prevention (CDC). 1999a. Geographic variation in penicillin resistance in Streptococcus pneumoniae-selected sites, United States, 1997. Morbidity and Mortality Weekly Report 48(30): 656-661.
10. Centers for Disease Control and Prevention (CDC). 1999b. Active Bacterial Core Surveillance (ABCs) Report, Emerging Infections Program Network, Streptococcus pneumoniae - 1997 and 1998. On-line reports at http://www.cdc.gov/ncidod/dbmd/ abcs.
11. Cetron MS, Jernigan DB, Breiman RF et al, 1996. Action plan for drug-resistant Streptococcus pneumoniae. Emerging Infectious Diseases 1(2): 64-65.
12. Chadwick DJ, Goode J (eds.) 1997. Antibiotic Resistance: Origins, Evolution, Selection and Spread. Wiley: New York.
13. Doern GV, Brueggemann A, Holley Jr HP, Rauch AM. 1996a. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40(5): 1208-1213.
14. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. 1996b. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. Antimicrobial Agents and Chemotherapy 40(4): 891-894.
15. Doern GV, Brueggemann AB, Huynh H et al. 1999. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerging Infectious Diseases 5(6): 757-765.
16. Earn DJD, Rohani P, Bolker BM, Grenfell BT. 2000. A simple model for complex dynamical transitions in epidemics. Science 287(28 January): 667-670.
17. Ekdahl K, Ahlinder I, Hansson HB et al. 1997. Duration of nasopharyngeal carriage of pencillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Clinical Infectious Diseases 25: 1113-1117.
18. Ekdahl K, Hansson HB, Mölstad S et al. 1998. Limiting the spread of pencillin-resistant Streptococcus pneumoniae: experiences from the South Swedish Pneumococcal Intervention Project. Microbial Drug Resistance 4(2): 99-104.
19. Fenoll A, Martín Bourgon C, Muñóz R et al. 1991. Serotype distribution and antimicrobial resistance of Streptococcus pneumoniae isolates causing systemic infections in Spain, 1979-1989. Review of Infectious Diseases 13: 56-60.
20. Fenoll A, Jado I, Vicioso D et al. 1998. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). Journal of Clinical Microbiology 36(12): 3447-3454.
21. Ferber D. 2000. Superbacteria on the hoof? Science 288(5 May): 792-794.
22. FitzGerald S. 2000. A new tool to protect baby from infections. Philadelphia Inquirer 18 February 2000.
23. Frimodt-Møller N, Espersen F, Jacobsen B et al. 1997. Problems with antibiotic resistance in Spain and their relation to antibiotic use in humans elsewhere. Clinical Infectious Diseases 25: 939-940.
24. Garrett L. 1994. The Coming Plague: Newly Emerging Diseases in a World Out of Balance. Penguin Books: New York.
25. Geslin P, Buu-Hoi A, Frémaux A, Acar JF. 1992. Antimicrobial resistance in Streptococcus pneumoniae: an epidemiological survey in France, 1970-1990. Clinical Infectious Diseases 15: 95-98.
26. Guillemot D, Carbon C, Balkau B et al. 1998. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. Journal of the American Medical Association 279(5): 365-370.
27. Hardin G. 1968. The tragedy of the commons. Science 162(13 December): 1243-1248.
28. Homer JB, St Clair C. 1991. A model of HIV transmission through needle sharing. Interfaces 21(3): 26-49.
29. Koornhof HJ, Wasas A, Klugman K. 1992. Antimicrobial resistance in Streptococcus pneumoniae:. a South African perspective. Clinical Infectious Diseases 15: 84-94.
30. Kristinsson KG. 1997. Effect of antimicrobial use and other risk factors on antimicrobial resistance in pneumococci. Microbial Drug Resistance 3(2): 117-123.
31. Lee H-J, Park J-Y, Jang S-H et al. 1995. High incidence of resistance to multiple antimicrobials in clinical isolates of Streptococcus pneumoniae from a university hospital in Korea. Clinical Infectious Diseases 20: 826-835.
32. Levin BR, Lipsitch M, Perrot V et al. 1997. The population genetics of antibiotic resistance. Clinical Infectious Diseases 24(Suppl. 1): S9-16.
33. Levy SB. 1992. The Antibiotic Paradox: How Miracle Drugs are Destroying the Miracle. Plenum Publishers: New York.
34. Levy SB. 1998. The challenge of antibiotic resistance. Scientific American, (March 1998): 46-53.
35. Long SS. 1999. Current status of pneumococcal vaccines. Clinical Updates in Pediatric Infectious Diseases 2(6): 1-4.
36. Marton A. 1992. Pneumococcal antimicrobial resistance: the problem in Hungary. Clinical Infectious Diseases 15: 106-111.
37. McCaig LF, Hughes JM. 1995. Trends in antimicrobial drug prescribing among office-based physicians in the United States. Journal of the American Medical Association 273(3): 214-219.
38. Morell V. 1997. Antibiotic resistance: road of no return. Science 278: 575-576.
39. National Center for Health Statistics (NCHS). 1997. 1997 National Ambulatory Medical Care Survey. NCHS CD-ROM Series 13 No. 21 (machine-readable data set). Also: CD-ROMs from NCHS Series 13 for 1990 (No. 2), 1991 (No. 3), 1992 (No. 4), 1993 (No. 6), 1994 (No. 8), 1995 (No. 11), and 1996 (No. 14). National Center for Health Statistics: Hyattsville, Maryland.
40. Neu HC. 1992. The crisis in antibiotic resistance. Science 257: 1064-1073.
41. Okie S. 1997. Experts urge steps to stem antibiotic resistance. Washington Post (Health section), 26 August 1997.
42. Rahal JJ, Urban C, Horn D et al. 1998. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. Journal of the American Medical Association 280(14): 1233-1237.
43. Reichmann P, König A, Liñares J et al. 1997. A global gene pool for high-level cephalosporin resistance in commensal Streptococcus species and Streptococcus pneumoniae. Journal of Infectious Diseases 176: 1001-1012.
44. Ritchie-Dunham JL, Méndez Galvan JF. 1999. Evaluating epidemic intervention policies with systems thinking: a case study of dengue fever in Mexico. System Dynamics Review 15(2): 119-138.
45. Ritchie-Dunham JL, Rabbino HT. 2001 (forthcoming). GRASP: The Art and Practice of Strategic Clarity. Wiley: Chichester.
46. Seppälä H, Klaukka T, Vuopio-Varkila J et al. 1997. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in Group A streptococci in Finland. New England Journal of Medicine 337(7): 441-446.
47. Song J-H, Lee NY, Ichiyama S et al. 1999. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clinical Infectious Diseases 28: 1206-1211.
48. Spika JS, Facklam RR, Plikaytis BD et al. 1991. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. Journal of Infectious Diseases 1G3: 1273-1278.
49. Sterman JD. 2000. Business Dynamics: Systems Thinking and Modeling for a Complex World. McGraw-Hill: Boston.